| Price | 53.00p on 20-01-2026 at 12:26:21 |
|---|---|
| Change | -2.50p -4.5% |
| Buy | 54.00p |
| Sell | 52.00p |
| Last Trade: | Buy 5.00 at 54.00p |
| Day's Volume: | 689,148 |
| Last Close: | 55.50p |
| Open: | 57.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 53.00p - 57.00p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £229.84m |
| VWAP: | 53.96839p |
| Shares in Issue: | 433.66m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 5 | 54.00p | Ordinary |
12:26:20 - 20-Jan-26 |
| Buy* | 4,005 | 53.425p | Ordinary |
12:12:51 - 20-Jan-26 |
| Buy* | 2,197 | 53.425p | Ordinary |
12:09:00 - 20-Jan-26 |
| Buy* | 183 | 53.425p | Ordinary |
11:55:00 - 20-Jan-26 |
| Buy* | 101 | 53.4373p | Ordinary |
11:54:33 - 20-Jan-26 |
| Buy* | 46 | 53.4373p | Ordinary |
11:48:36 - 20-Jan-26 |
| Sell* | 1,009 | 52.2667p | Ordinary |
11:28:37 - 20-Jan-26 |
| Buy* | 9,333 | 53.44p | Ordinary |
11:27:16 - 20-Jan-26 |
| Sell* | 7,631 | 52.575p | Ordinary |
11:26:47 - 20-Jan-26 |
| Buy* | 355 | 53.5973p | Ordinary |
11:25:48 - 20-Jan-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |
| 20th Oct 2025 7:01 am | RNS | Equity fundraise of £16 million |
| 20th Oct 2025 7:00 am | RNS | Avacta Presents Phase 1a Data for Faridoxorubicin |
| 13th Oct 2025 7:00 am | RNS | Avacta to present data at EORTC-NCI-AACR |
